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Introduction
Eosinophilic esophagitis (EoE) has emerged over the last decade as a major cause of
gastrointestinal morbidity in both children and adults. EoE is a chronic inflammatory
condition defined by symptoms of esophageal dysfunction, an eosinophilic infiltrate in the
esophageal epithelium, and the absence of other potential causes of eosinophilia.1 First
described in 1978,2 EoE was only rarely reported for the subsequent two decades.3–7 In the
late 1990s, however, the condition was increasingly recognized, first in children and then in
adults, and the incidence and prevalence have been rapidly increasing.8–14 The prevalence of
EoE varies based on the study design and setting.15 In the general population, case estimates
have ranged from 0.2 – 4/1,000 in asymptomatic patients,10, 16 but in those undergoing
endoscopy for upper GI symptoms, EoE is found in 5–16%.17–19 Current estimates suggest
that the overall prevalence of EoE in the general population is between 43 and
52/100,000.11, 20
EoE is thought to be an immune-mediated disorder where food or environmental antigens
stimulate a Th2 inflammatory response.1, 21 Key cytokines such as IL-4, IL-5, and IL-13
stimulate the production of eotaxin-3 in the esophageal mucosa. Eotaxin-3, a potent
chemokine which is markedly upregulated in EoE, recruits eosinophils to the esophageal
mucosa.21, 22 In turn, activated eosinophils secrete proinflammatory and profibrotic
mediators, cause local tissue damage, and recruit additional inflammatory cells (mast cells
and fibroblasts), perpetuating the inflammatory response and resulting in esophageal
remodelling.23–26 The interaction between environmental exposures and genetic
susceptibility has been illustrated both in animal models and in patients with EoE.22, 27–29
With the increasing knowledge base for EoE, paradigms for diagnosis and treatment of EoE
are also evolving. The purpose of this paper is to review the approach to diagnosis and
management of EoE, with a focus on the evidence that informs current practice. The
consensus diagnostic guidelines will be presented, and a discussion of the clinical,
endoscopic, and histologic features of EoE will illustrate practical points and potential
© 2012 The American Gastroenterological Association. Published by Elsevier Inc. All rights reserved.
Corresponding Author: Evan S. Dellon MD, CB#7080, Bioinformatics Building, 130 Mason Farm Rd. UNC-CH, Chapel Hill, NC
27599-7080, Phone: (919) 966-2513, Fax: (919) 843-2508, edellon@med.unc.edu.
Disclosures: No conflicts of interested pertaining to this manuscript. Dr. Dellon has received research support from AstraZeneca,
Meritage Pharma, Olympus, NIH, ACG, and AGA. Dr. Dellon has been a consultant for Oncoscope.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2013 October 01.
Published in final edited form as:













pitfalls related to diagnosis of EoE. The three major treatment approaches to EoE –
pharmacologic therapy, dietary modification, and endoscopic dilation – will also be
presented in detail.
Diagnosis of eosinophilic esophagitis
The first consensus guidelines for diagnosis of EoE were published in 2007 and represented
a major milestone.30 Prior to this, there was marked variability in the literature with regard
to how the disease was defined,31 and after this there has been some degree of increasing
uniformity in diagnosis, though this has not been complete.32, 33 The 2007 guidelines
emphasized that EoE was a clinicopathologic condition, meaning that both clinical and
histologic features were needed for diagnosis and that neither could be interpreted in
isolation. Three specific criteria were required to diagnose EoE: 1) symptoms of esophageal
dysfunction (e.g. dysphagia, food impaction, heartburn, chest pain, regurgitation, etc); 2) at
least 15 eosinophils per high-power microscopy field (eos/hpf) in at least one esophageal
biopsy; and 3) exclusion of gastroesophageal reflux disease (GERD) as a cause of
esophageal eosinophilia by either lack of response to a high-dose proton-pump inhibitor
(PPI) trial or negative pH monitoring.30 As knowledge about EoE increased, there was a
recognition that the guidelines would need to evolve. In particular, the complex relationship
between EoE, GERD, and esophageal eosinophilia became increasingly acknowledged,34
EoE and GERD were observed to coexist in some cases, and a new phenomenon termed
PPI-responsive esophageal eosinophilia (PPI-REE; discussed below) was described.
To address these issues, the consensus guidelines were updated in 2011 and presented a
conceptual definition of EoE as a “chronic immune/antigen-mediated esophageal disease
characterized clinically by symptoms related to esophageal dysfunction and histologically
by eosinophil-predominant inflammation.”1 To diagnose EoE, three criteria were retained
but with some modifications (Table 1): 1) symptoms of esophageal dysfunction; 2) a
maximum eosinophil count of ≥15 eos/hpf, with few exceptions; and 3) eosinophilia limited
to the esophagus with exclusion of other possible causes of esophageal eosinophilia,
including PPI-REE. These new guidelines address the limitations of excluding GERD in all
cases, provide some degree of flexibility in histologic interpretation, and recognize PPI-REE
as a new entity. Given the ongoing advances in EoE-related knowledge, it is expected that
these guidelines will continue to be updated as new data are generated.
Clinical features of eosinophilic esophagitis
While the diagnostic guidelines require symptoms of esophageal dysfunction, EoE can
present with a range of symptoms that vary by patient age.1, 8, 13, 35, 36 In adolescents and
adults, dysphagia is the hallmark of EoE, affecting between 25% and 100% of patients
depending on the study design and setting.9, 13, 17, 19, 31 Acute food impaction is the most
extreme presentation of solid food dysphagia, and EoE is now the cause in approximately
half of cases of patients with food impaction requiring emergent evaluation and bolus
clearance.37–39 On history, it is important not only to ask patients about trouble swallowing,
but also about avoidance of specific foods, ability to dine at restaurants, and thoroughness of
chewing in order to characterize dietary modifications that minimize overt symptoms of
dysphagia. In younger children, the presentation is more nonspecific, with symptoms of
feeding intolerance, failure to thrive, abdominal pain, nausea, vomiting, and
regurgitation.9, 35, 40 In patients of both ages, between 10% and 100% have heartburn, again
depending on study design and setting.9, 13, 17, 19, 31 Conversely, EoE is the cause of
heartburn 1–8% of patients with PPI-refractory symptoms of GERD.9, 19, 41–44 It is
important to note that no symptom in isolation is specific for the diagnosis of EoE.
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EoE has been described across the age spectrum, but is most common before the age of
40.9, 12, 31 It is also thought to be more common in males and Caucasians,17–19, 40, 45–47 but
as more data are accrued from centers with diverse patients populations, EoE is being
reported with increasing frequency in African-American and other minority
populations.19, 46, 48 Associated allergic diseases such as atopic dermatitis, atopic rhinitis/
sinusitis, asthma, and food allergies are also very common in patients with EoE. In children,
up to 50–80% have atopy, with a somewhat lower rate in adults.13, 40, 49–52 Atopy is not
universal in EoE, however, and the role of the allergist is often dependent on local expertise
and practice patters. The most recent guidelines suggest that referral to an allergist be
considered to help maximize therapy for non-esophageal allergic diseases and assist with the
interplay between multiple allergic conditions.1
Endoscopic features of eosinophilic esophagitis
When a suggestive clinical picture leads to suspicion of EoE, upper endoscopy
(esophagogastroduodenoscopy; EGD) is needed to inspect the esophagus, evaluate for
alternative causes, and obtain esophageal biopsies. There are number of typical endoscopic
findings of EoE, although similar to symptoms, none are specific for the condition. Findings
can occur individually or in combination and include: esophageal rings which can be fixed
or transient; narrow-caliber esophagus; longitudinal furrows running parallel to the axis of
the esophagus; mucosal pallor, congestion or decreased vascularity; white plaques or
exudates which can inadvertently be mistaken for candidal esophagitis; and fragile
esophageal mucosa, termed “crêpe-paper mucosa”, where a tear occurs with passage of the
endoscope (Figure 1). It is important to note that in approximately 7–10% of subjects with
EoE, the esophagus will appear normal,31, 53 and if biopsies are not obtained, the diagnosis
will be missed. In addition, two recent studies showed that the inter- and intra-observer
reliability of detecting findings of EoE are only fair.54, 55 Compounding this, in a recent
meta-analysis of 100 studies reporting EoE findings in over 4600 EoE patients and 2700
controls, the sensitivity, specificity, and predictive values of endoscopic findings in EoE
were insufficient to make diagnostic decisions.53 Therefore, it is recommended that
esophageal biopsies be obtained in all patients suspected of having EoE regardless of the
endoscopic appearance.1 Moreover, when performing biopsies, at least 2–4 from the distal
and 2–4 from the proximal esophagus should be taken to maximize diagnostic sensitivity.1
This practice is supported by studies showing that the esophageal eosinophilic infiltrate in
EoE is patchy,56, 57 that eosinophil levels vary between the proximal and distal
esophagus,58, 59 and that increasing numbers of biopsies improve the likelihood of making
the correct diagnosis,58, 60 but prospective studies comparing different biopsy protocols for
diagnosis of EoE have not been conducted.
Histologic features of eosinophilic esophagitis
On examination of biopsy specimens, an eosinophilic infiltrate in the esophageal epithelium
with ≥ 15 eos/hpf suggests the diagnosis of EoE (Figure 2). However, like clinical
symptoms and endoscopic findings, esophageal eosinophilia alone is not diagnostic for EoE
and the biopsy findings must be placed in the clinical context.1, 61, 62 There are also a
number of associated histopathologic features of EoE, including: eosinophil degranulation
where extracellular deposition of eosinophil granule proteins is observed; eosinophil
microabscesses, defined by clusters of ≥ 4 eosinophils; basal zone hyperplasia or rete peg
elongation; spongiosis; and fibrosis of the lamina propria if sufficient subepithelial tissue is
present for evaluation (Figure 2).
Potential diagnostic pitfalls
When the correct combination of clinical and histologic findings is present, EoE can be
diagnosed. However, in many cases the diagnostic process is challenging because findings
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may not be clear-cut and there can be overlap between clinical entities such as EoE and
GERD. For each of the diagnostic criteria and associated clinical findings, there are
important pitfalls to avoid in the diagnostic process. First, while there is excellent inter- and
intra-observer reliability for pathologists determining eosinophil counts using a specified
protocol,63 the high-power field (hpf) size varies depending on make and model of the
microscope used by a given pathologist.31 Therefore, for any given eosinophil density (in
eos/mm2), the specific eosinophil count (in eos/hpf) will depend on the hpf size and it is
possible that a count that falls below the diagnostic threshold on one microscope would be
above the threshold on a different one.31 This is one reason that communication with
pathologists about findings, understanding how eosinophils are quantified, and also
reporting associated biopsy findings beyond the eosinophil count alone are all important.
A key point is that the finding of esophageal eosinophilia does not immediately confer a
diagnosis EoE. There is a differential diagnosis of esophageal eosinophilia that must be
considered, which includes other eosinophilic gastrointestinal disorders such as eosinophilic
gastroenteritis, GERD, PPI-REE, hypereosinophilic syndrome, infection, achalasia, drug
hypersensitivity, Crohn’s disease, connective tissue disease, and others.1, 30 While most of
these entities are uncommon and can be readily excluded with a basic evaluation, from a
practical standpoint GERD and PPI-REE present the most commonly encountered
challenges. For GERD, there is substantial clinical (heartburn, dysphagia, chest pain,
regurgitation) and histologic (esophageal eosinophilia) overlap with EoE.1, 34, 44 Previously,
it was felt that if a patient was treated with a PPI with subsequent resolution of symptoms
and esophageal eosinophilia, then EoE was excluded and the diagnosis was GERD.
However, the situation is no long straightforward due to the recognition of PPI-REE.
In 2006, a case series presented three children with dysphagia, food impaction, vomiting and
suspected EoE.64 All had high levels of esophageal eosinophilia, and all completely
responded to PPI therapy. The study raised the question of whether this phenomenon was
GERD or an EoE phenotype that was PPI-responsive. Since then, several studies have
shown that approximately one-third of patients or more with clinical symptoms of
esophageal dysfunction and esophageal eosinophilia respond to PPI therapy.65–70 As of yet,
it is not know if these patients have an atypical presentation of GERD, a variant of EoE that
responds to PPI therapy, or a completely different entity, but clinical features and pH testing
do not appear to predict response.65, 67 Intriguing preliminary data show an anti-
inflammatory effect of PPIs independent of an anti-acid effect as a potential explanation for
this clinical observation.71 The recognition of PPI-REE implies that the diagnosis of EoE
now requires a PPI trial, not to exclude GERD necessarily, but to evaluate for PPI-response
in patients with esophageal eosinophilia.1 Typically, an 8 week course of 20–40 mg twice
daily of any of the available agents is felt to be adequate for this trial, but there are few data
to support specific dosing regimens or agents.66, 67 While much more needs to be learned
about this patient sub-group, currently PPI-REE must be excluded formally to diagnose
EoE.
Because of these diagnostic challenges and potential pitfalls, there is ongoing research to
develop new diagnostic approaches. Though these methods are not yet validated for clinical
use, they are promising and may have substantial utility in the near future. These include
clinical scoring systems,13, 72, 73 enhanced or novel endoscopic imaging techniques,54, 74, 75
functional luminal imaging of the esophagus,76 biomarker assessments on esophageal
biopsies,77–80 non-invasive serum biomarkers,81–83 and genetic testing.22, 84
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Treatment of eosinophilic esophagitis
Treatment of EoE is focused on improving both patient symptoms and histology on
esophageal biopsies, as well as correcting or preventing complications such as esophageal
strictures or food impactions leading to esophageal rupture, but there are currently few data
to support specific treatment endpoints.1, 85 Ideally, the goal would be complete symptom
resolution and normalization of the esophageal epithelium with elimination of all
eosinophils, but in practice symptom improvement and histologic response do not always
correlate,72, 85–89 and, as discussed below, the treatment trials to date have used different
primary outcomes. Therefore, aiming to improve patient symptoms and substantially reduce
the level of esophageal eosinophilia, while minimizing treatment side effects and adverse
impact on quality of life, is a sensible strategy until more data can inform specific
recommendations. This strategy will typically require a follow-up endoscopy after an initial
course of therapy to assess for histologic response.
Overall, there are three general categories of treatment, often referred to as “the three D’s”:
drugs, diet, and dilation.1, 90, 91 While there are as yet no FDA-approved medications or
devices to treat EoE, strong data supporting all three categories of EoE treatment have been
developed over the past decade.
Pharmacologic therapy
Topical corticosteroids—Corticosteroids used topically are a mainstay of EoE treatment
and first line agents in many cases. These are typically asthma preparations (multi-dose
inhalers or nebulizer solutions) that are taken orally so the medication is swallowed rather
than inhaled. The initial experience was presented in a pediatric case series,92 and
subsequent observational studies reported that medications such as fluticasone and
budesonide, when swallowed, improved patient symptoms, decreased esophageal
eosinophilia, and were generally well-tolerated.9, 93–98
There have now been 9 randomized clinical trials examining the use of topical steroids for
EoE, including fluticasone vs placebo,99, 100 fluticasone vs prednisone,59 fluticasone vs
esomeprazole,68, 69 budesonide vs placebo,87, 101, 102 and a study of two forms of
budesonide.103 Table 2 summarizes the details of these trials, and presents the most stringent
outcome (ie the greatest degree of improvement in eosinophilia) rather than the primary
outcome, for ease of comparison given that the primary outcome varied in each trial.
The first treatment trial in EoE randomized 21 children to receive swallowed fluticasone 880
ucg/d divided twice daily and 15 children to receive placebo for 3 months.99 Fifty percent of
patients receiving fluticasone achieved the primary endpoint of complete histologic
remission (≤ 1 eos/hpf) compared to just 9% of patients receiving placebo, but only the
symptom of vomiting was noted to improve. A similarly designed study was recently
conducted in adults where 21 patients received fluticasone 1760 ucg/d divided twice daily
and 15 received placebo for 6 weeks.100 The primary endpoint of a >90% decrease in the
mean eosinophil count was reached by 62% treated with fluticasone and 0% of the placebo
group. Improvement in dysphagia was not significantly different between groups.
An approach to topical steroids using swallowed budesonide was developed in children to
simplify medication administration.97, 104 Here, a budesonide aqueous solution was mixed
with a sugar substitute (sucralose) to make a sweet and easy to swallow slurry, termed “oral
viscous budesonide” (OVB). A subsequent clinical trial randomized 15 children to 1–2 mg
of OVB/d depending on height and 9 children to placebo for 3 months. The primary
outcome of histologic response (≤ 6 eos/hpf) was achieved by 87% in the treatment arm and
none in the placebo group. The mean symptom score also improved in OVB compared to
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placebo. A larger RCT in children examining a muco-adherent formulation of a budesonide
suspension also showed an outstanding histologic response, but both study arms had
substantially improved symptoms, highlighting a lack of correlation between symptoms and
histology of EoE that has been repeatedly observed.87 The efficacy of budesonide has also
been confirmed in adults. One study randomized patients to a protocol where they
swallowed budesonide droplets that had been aerosolized by a nebulizer and showed that
histology and symptoms substantially improved compared to placebo after only 15 days.102
A recent study that compared OVB with nebulized/swallowed budesonide found that OVB
was more effective for improving histology, but that symptoms again improved in both
study groups.103 There are no commercial preparations of OVB yet available in the U.S., so
if this medication option is chosen, patients must be instructed on how to mix the aqueous
budesonide solution with a sugar substitute.
Topical steroids have been found to be well tolerated. There have been no reports of adrenal
suppression associated with the initial course of topical steroid administration,87, 100, 101, 103
but longer term safety data are needed for a variety of potential steroid-related side effects.1
The rate of candidal esophagitis with topical steroids has ranged from 0–32% in prospective
studies, though the majority of these cases were asymptomatic and detected incidentally at
follow-up endoscopy.59, 87, 99–103 Herpes esophagitis has also been reported as a rare
complication.105
If topical steroids are stopped after the initial treatment course, the majority of patients will
have symptom recurrence. This is a theme that is repeated for all treatment modalities:
because EoE is chronic, symptoms and histologic findings tend to recur after discontinuing
treatment. One study investigating disease recurrence after topical steroid use contacted 32
adult patients who had previously been treated with 6 weeks of swallowed fluticasone.106 At
a mean duration of 3.3 years of follow-up, 91% reported recurrent dysphagia, with a mean
time to symptom recurrence of 9 months, and 69% required repeat fluticasone treatment. To
date, there has been one trial of maintenance therapy in EoE. In this study, subjects who
previously responded to nebulized/swallowed budesonide102 were randomized to continue
low-dose budesonide at 0.5 mg/d or to receive placebo for a year.107 Histologic recurrence
was universal in the placebo group compared with the budesonide group (100% vs 50%),
and symptom recurrence was also more common (64% vs 36%). These data raise the
question of whether maintenance therapy should be considered in patients with EoE.
Systemic corticosteroids—Systemic corticosteroids were the first of the steroid
therapies used for EoE.3, 108 A pediatric case series showed that treatment with
methylprednisolone led to either complete or marked symptom improvement in 19 of 20
children with a mean time to response of just 8 days.109 However, 6 months post-treatment,
the majority of children had recurrent symptoms and eosinophilia. In the one RCT of
systemic steroids, prednisone was compared to swallowed fluticasone in 80 children.59
Prednisone was equivalent to fluticasone for decreasing esophageal eosinophilia and
improving the presenting symptom, but was associated with more adverse events. Because
of this result and the concern about risks of long-term use, systemic steroids are typically
reserved for second-line therapy in cases where topical steroids are not effective, or first-line
therapy primarily in children with severe symptoms, malnutrition, or feeding intolerance
where a very rapid response may be needed or topical steroid administration is logistically
difficult.
Leukotriene antagonists and mast cell stabilizers—Because of the presumed
immune-mediated etiology of EoE, allergy medications are a theoretically attractive option
for EoE treatment but few data support this approach. The initial report of treatment with the
leukotriene antagonist montelukast showed efficacy in 6 of 8 adults, but with a dose range
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that averaged 20–40 mg/d and was associated with nausea and vomiting.110 Two recent
studies using standard dosing, one in children111 and one in adults112 had mixed results,
with 3 of 8 children and no adults responding. There have also been two studies which
assessed cysteinyl leukotrienes and leukotriene synthesis enzyme staining, respectively, in
esophageal biopsies and did not find differential levels in EoE cases compared with
controls.113, 114 For these reasons, montelukast is not routinely recommended for use and is
reserved as a second line agent in selected cases.
Despite mast cells being increasingly recognized as critical in the pathogenesis of
EoE,24–26, 115 mast cell stabilizers such as cromolyn sodium are not felt to be effective
based on case series data and are not recommended for routine use in EoE.9
Immunomodulators—Use of immunomodulators such as azathioprine or 6MP has been
reported in a single case series of 3 steroid-refractors adults with EoE.116 In all cases,
subjects were treated with azathioprine (2–2.5 mg/kg/d), had an excellent response in
esophageal eosinophilia, and relapsed after treatment was discontinued. After relapse, they
were successfully treated with corticosteroids and maintained on azathioprine with good
success. While intriguing, the data are as yet too limited to recommend an “induce and
maintain” strategy analogous to IBD, and routine use of immunomodulators is not
recommended in EoE, particularly due to potential side effects.
Biologics—With the rapid increase in knowledge about the pathogenesis of EoE, new
biologic therapies have been developed to target key factors in EoE pathways. The best
studied of these agents are antibodies to IL-5, a central cytokine in eosinophil physiology
and EoE pathophysiology. A case series of 4 patients treated with anti-IL-5 (mepolizumab)
suggested this approach had potential for improving symptoms and reducing levels of
esophageal eosinophilia.117 Since that time, there have been 3 placebo-controlled RCTs (see
Table 2).88, 118, 119 In all three studies, there was a mild to moderate decrease in eosinophil
counts, but strict endpoints of resolution of esophageal eosinophilia were not met. Further,
in the largest of the studies which examined the anti-IL-5 antibody reslizumab,88 symptoms
improved equally in both the treatment and placebo group. These agents are still considered
experimental, not yet commercially available, and are not recommend for routine use in
EoE.
Omalizumab, an antibody to IgE, was studied in EoE given that it has efficacy in other
atopic conditions such as allergic asthma and chronic urticaria. In this investigation, 16 EoE
patients were randomized to receive omalizumab, and 14 received placebo.120 After a 16
week treatment period, eosinophil counts and symptoms did not improve in either the
treatment or placebo arm. This agent is not recommended for use in EoE at this time.
Tumor necrosis factor (TNF) has been shown to be increased in esophageal biopsies from
patients with EoE, suggesting a possible clinical utility for anti-TNF agents.121 However, in
a case series of 3 adults with steroid-refractory EoE who were treated with infliximab, there
was no substantial improvement in either symptoms or histology.122 This agent is also not
recommended for use in EoE at this time.
Future pharmacologic agents—Novel therapeutic agents for treatment of EoE are
actively being sought, and monoclonal antibodies such as anti-IL-13 and anti-eotaxin-3 are
under development.1 Improved formulations and delivery methods for administering current
topical corticosteroids are also under investigation.87, 123 Finally, a new medication class, an
antagonist to the chemoattractant receptor-homologous molecule expressed on Th2 cells
(CRTH2) has recently been found to result in a mild improvement in esophageal
eosinophilia, and further studies will be needed to assess its clinical utility.124
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Because food allergens may contribute to the pathogenesis of EoE in many patients,21
identifying and avoiding dietary allergens is appealing to target an underlying etiology of
EoE. There are three general strategies for dietary elimination in EoE: elemental diet, six-
food elimination diet, and targeted elimination diet. The specific approach often depends on
local allergy and nutritional expertise and support, and patient and family preferences,
resources, and motivation. If a patient decides to embark on dietary therapy, referral to an
allergist may be considered to determine whether specific testing for food allergies is needed
and by what modality, to help manage the dietary elimination and reintroduction process,
and to fully evaluate and treat the patient for potential concomitant atopic disorders.
However, outside of dietary therapy and associated allergic conditions, not every EoE
patient will require evaluation by an allergist.1
An elemental formula comprised of amino-acids, basic carbohydrates, and medium chain
triglycerides is allergen free and has been shown to be extremely effective for treatment of
EoE in children. The first report of this approach showed that all 10 children treated had
either resolution or improvement in symptoms and esophageal eosinophilia within 2–6
weeks.7 A larger study of 51 children with EoE treated with an elemental diet showed that
49 (96%) had a marked improvement in symptoms and esophageal eosinophilia, with an
average time to symptom improvement of only 9 days.125 This response rate has
subsequently been confirmed in other large series.9, 126 Only one small study has examined
use of an elemental diet in adults with EoE, and this showed a 50% partial response rate,
perhaps due to difficulties with compliance.127
In practice, use of an elemental diet can be difficult; formulas are expensive, unpalatable and
may need to be administered via an enteral feeding tube, extremely restrictive, and can
adversely impact quality of life. Because of these issues, an empiric six-food elimination
diet (SFED) was developed to increase compliance and acceptability. This diet eliminates 6
of the most common food allergens: milk, eggs, wheat, soy, seafood, and nuts. It was first
studied on a retrospective basis, and compared very favorably to an elemental diet with 74%
of subjects having a histologic response to ≤ 10 eos/hpf, and 95% having a symptomatic
response.128 In addition, this approach was found to be more palatable than the elemental
diet. Subsequent work from the same group showed that after food reintroduction, the most
common food trigger was milk, with wheat, egg, and soy being less common.129 Recent
work in children has confirmed this response rate,126 and a prospective study of SFED in
adults with EoE now shows efficacy as well.130 In this study, 50 subjects were treated with
SFED, 64% had a complete histologic response (≤ 5 eos/hpf) and 94% had symptom
improvement. After a food reintroduction protocol, wheat and milk were the most
commonly identified allergens. Similar results have been reported in abstract form in
another study of adults treated with SFED.131
The last approach to dietary therapy is a targeted diet where food allergens identified on
allergy testing are eliminated. While it is beyond the scope of this paper to fully review the
various methods of testing for food allergies, it can be difficult to reliably detect specific
food allergies with current testing modalities, and the best approach is still
debated.1, 30, 126, 129, 130, 132 With that caveat, data also support the use of targeted
elimination. An initial study performed both skin prick and atopy patch testing on 26
children with EoE.133 After identification and elimination of potential culprit allergens, 24
of the subjects had a complete or partial response to therapy, with milk and egg being the
most commonly detected allergens by prick testing, and wheat and soy being the most
common with patch testing. While subsequent studies have showed success with this
approach, the response rates have been closer to the 55–75% range in children,9, 126, 134 and
potentially lower in adults.135, 136
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The final treatment approach for EoE, used in patients with esophageal strictures or narrow
caliber esophagus and symptoms of dysphagia, is esophageal dilation. While the techniques,
typically wire-guided bougie dilation or through-the-scope (TTS) balloon dilation, are
familiar to many gastroenterologists, special comment on the application of dilation to EoE
is warranted. When dilation was first described in EoE, multiple case series raised
substantial safety concerns by reporting high rates of complications such as esophageal
perforation, esophageal rents, and hospitalization for post-procedural chest pain.137–142 For
example, in the largest of these studies, 3 of 36 patients undergoing esophageal dilation had
a perforation (8%) and 1 had emesis-induced Boerhaave’s syndrome.142 As a result of this,
and in the context of observed mucosal fragility in EoE,139 the first consensus guidelines for
EoE recommended a very cautious approach to dilation only after institution medical or
dietary therapy for this condition.
Over the past several years, however, larger studies have reported on a more extensive and
carefully characterized experience with esophageal dilation in EoE,143–149 and there are now
two systematic reviews on dilation for patients with EoE.150, 151 While these studies are
retrospective, almost 500 patients, representing nearly 1000 dilations, have cumulatively
been reported and there have been 3 esophageal perforations. This rate (0.3%) is not
dissimilar to that quoted for standard endoscopy with dilation in a non-EoE population.152 In
addition, the large majority of the perforations that have been reported to date have been
managed non-operatively.
In addition to being safer than initially believed, esophageal dilation is also effective in
improving symptoms of dysphagia even though it has no impact on underlying eosinophilic
inflammation.147, 148, 150, 151 In one large study of esophageal dilation, a subgroup of 42
patients who were treated with dilation alone were contacted and symptoms were
assessed.147 Post-dilation, 81% were symptom-free at 3 months, 46% were symptom free at
1 year, and 41% were symptom free at 2 years. Importantly, this study also noted that 74%
of patients reported some degree of retrosternal pain after the endoscopy, and this was
described as moderate in 21% and severe in 17%. Nevertheless, all of the patients who were
questioned found the procedure to be acceptable and would have repeat dilation if indicated.
Taken in sum, these data show that esophageal dilation can be a safe and effective treatment
for EoE patients with strictures or narrow caliber esophagus, and its use is now supported by
the updated consensus recommendations.1 The typical approach is to defer esophageal
dilation at the baseline (diagnostic) endoscopy unless there is an area of critical narrowing,
in favor of performing dilation during the follow-up endoscopy performed to assess
response to medical or dietary therapy. The choice of dilation as the initial therapy in all
cases is still controversial. There are few data to guide dilator choice in EoE, and there are
proponents of both bougie and TTS balloon dilation.148, 153 Balloon dilation offers the
theoretic advantages of reduced shear force and ability to accurately determine esophageal
caliber, directly visualize the dilation, and stop dilation once a non-transmural esophageal
tear is noted without having to reintroduce the endoscope after each dilator size increase
(Figure 3). In contrast, bougies allow dilation of the entire esophageal with one pass, can
provide a tactile sensation of resistance to the endoscopist, and are less expensive. Because
further studies are needed to determine the safest and most effective dilation approach, it
remains prudent to approach esophageal dilation in EoE judiciously and discuss the risks
and benefits, including the high likelihood of post-procedural chest discomfort, with patients
prior to endoscopy.
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Over the past two decades, EoE has made a remarkable transformation from a rarely seen,
case-reportable diagnosis to a commonly encountered condition in GI practice. Because no
individual clinical, endoscopic, or histologic feature alone is pathognomonic, EoE is a
clinicopathologic condition; in order to diagnose EoE all features must be considered
together. The most recent consensus guidelines state that EoE is diagnosed when there are
symptoms of esophageal dysfunction, ≥ 15 eos/hpf on esophageal biopsy, and when other
causes of esophageal eosinophilia, including PPI-REE, are excluded. Once the diagnosis is
confirmed, the three main treatment options are drugs, diet, and dilation.
Figure 4 depicts a practical approach to diagnosis and treatment of EoE and summarizes the
concepts discussed in this review. When EoE is suspected on a clinical basis, EGD is
performed for initial evaluation. To maximize diagnostic sensitivity, at least 2–4 biopsies
should be taken from both the proximal and distal esophagus regardless of the endoscopic
appearance of the esophagus. If eosinophilia, in most cases with ≥ 15 eos/hpf, is noted on
biopsy, EoE can be suspected, but not yet formally diagnosed. First, other conditions that
cause esophageal eosinophilia must be excluded, and then a PPI trial, typically with twice
daily therapy for 8 weeks, must be instituted to evaluate for the possibility of PPI-REE. At
repeat endoscopy, if symptoms and esophageal eosinophilia have improved substantially or
resolved, then the patient does not have EoE as it is currently defined. Further clinical
evaluation can be performed as needed to determine if the patient has GERD. If there is not
evidence of GERD, PPI-REE can be diagnosed. Given that the patient has clinically
improved and that there are few data supporting the next step in management, the PPI is
typically continued at the lowest dose that effectively controls symptoms and the patient is
monitored. This part of the algorithm is likely to evolve in the future as more is learned
about PPI-REE. In contrast, at repeat endoscopy if symptoms and esophageal eosinophilia
persist with levels still ≥ 15 eos/hpf, then EoE is formally diagnosed. First line treatment can
either be with topical/swallowed corticosteroids or with dietary elimination. If steroids are
chosen, the dose range is typically 880–1760 ucg/d of fluticasone or 1–2 mg/d of budesonide
mixed with 5g of sucralose, both administered twice daily with the exact dose determined by
patient age or size. If dietary therapy is chosen, depending on patient preference, local
expertise, allergy testing results, and illness severity, options include targeted elimination,
empiric six-food elimination (eliminating milk, eggs, wheat, soy, seafood, and nuts), and
elemental diets. Both pharmacologic and dietary therapies are initially prescribed for 6–8
weeks, and then follow-up endoscopy is performed. If there is a substantial improvement in
symptoms and esophageal eosinophilia, then maintenance therapy can be considered and
patients can be monitored. If there is not an adequate clinical response, then additional
therapies can be considered. If steroids were chosen initially, then dietary elimination could
be considered, and vice versa. If neither of these options is successful, there are few data to
guide subsequent therapy and choices must be tailored to the individual patient. Endoscopic
dilation could be considered if there are critical strictures, esophageal narrowing, or
persistent fixed rings that are thought to explain dysphagia. Additionally, superimposed
infections, such as candidal esophagitis, should be excluded. Systemic steroids could be
considered if symptoms are severe or need to be treated quickly because of malnutrition. In
select cases, other agents can also be considered. Looking to the future, there is hope that
biomarkers will be able to make the diagnostic process less invasive and potentially
individualize initial treatment choices. As new studies are conducted and additional data
accumulate, the algorithm for diagnosis and treatment of EoE will continue to evolve.
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Endoscopic findings of EoE include fixed esophageal rings (A), narrow caliber esophagus
(B; also note the pale/congested mucosa with decreased vascularity), longitudinal furrows
running parallel to the axis of the esophagus (C), white plaques or exudates (D), and crêpe-
paper mucosa which tears passage of the endoscope alone (E). Often, a combination of these
findings can be seen at the same time (F).
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Histologic findings of EoE include a brisk infiltrate of eosinophils in the esophageal
epithelium, eosinophilic microabscesses (clusters of 4 or more eosinophils), spongiosis, and
basal zone hyperplasia (A). In addition to an eosinophilic infiltrate, spongiosis, and basal
zone hyperplasia, this sample shows eosinophil degranulation with extracellular eosinophil
granules dispersed throughout the epithelium (B). If an esophageal biopsy contains tissue
deeper than epithelium, fibrosis of the lamina propria can often be seen (C).
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Endoscopic dilation for treatment of EoE. A through-the-scope balloon dilator has been
inflated to a diameter of 12mm in a patient with EoE and a narrow caliber esophagus (A).
When the balloon is deflated, a longitudinal rent is noted, indicating good dilation effect (B).
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An approach to diagnosis and management of EoE.
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Diagnostic guidelines for EoE1
Because EoE is a clinicopathologic disease, the following clinical and histologic information are required for diagnosis:
• Symptoms related to esophageal dysfunction
• ≥ 15 eosinophils per high-power microscopy field in at least one esophageal biopsy specimen, with few exceptions
• Eosinophilia limited to the esophagus
• Other causes of esophageal eosinophilia excluded, particularly PPI-responsive esophageal eosinophilia
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